Prognosis of histological cirrhosis in type 1 autoimmune hepatitis

S. K. Roberts, Terry M Therneau, A. J. Czaja

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Background and Aims: Cirrhosis connotes irreversible damage to the liver and a shortened life expectancy. The aim of this study was to evaluate the impact of cirrhosis on treatment response and survival in type 1 autoimmune hepatitis. Methods: One hundred twenty-eight patients were evaluated for histological cirrhosis. Response to treatment, predictors for cirrhosis, and outcomes were determined. Results: Thirty-seven patients (29%) had histological cirrhosis at entry, whereas 36 of the 91 patients without cirrhosis (40%) developed it during 39 ± 32 months. Development of cirrhosis was predicted by lower serum albumin levels (P = 0.04) and higher prothrombin times (P < 0.001) at presentation. The frequencies of remission, relapse after drug withdrawal, and treatment failure were comparable in patients with and without cirrhosis at entry. The overall 10-year survival (93%) was similar to that of an age- and sex-matched cohort from the population at large (94%). Ten-year survival was not different between those with and those without cirrhosis at entry (89% and 90%, respectively), even with transplantation as an end point. Conclusions: Patients with histological cirrhosis at presentation respond to corticosteroid therapy as well as patients without cirrhosis. Low serum albumin levels and hypoprothrombinemia at presentation predict the development of cirrhosis. Histological cirrhosis does not diminish survival expectations.

Original languageEnglish (US)
Pages (from-to)848-857
Number of pages10
JournalGastroenterology
Volume110
Issue number3
DOIs
StatePublished - 1996

Fingerprint

Autoimmune Hepatitis
Fibrosis
Survival
Serum Albumin
Hypoprothrombinemias
Prothrombin Time
Life Expectancy
Treatment Failure
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. / Roberts, S. K.; Therneau, Terry M; Czaja, A. J.

In: Gastroenterology, Vol. 110, No. 3, 1996, p. 848-857.

Research output: Contribution to journalArticle

Roberts, S. K. ; Therneau, Terry M ; Czaja, A. J. / Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. In: Gastroenterology. 1996 ; Vol. 110, No. 3. pp. 848-857.
@article{fd4a509cffe44537a0e7d970a86c4522,
title = "Prognosis of histological cirrhosis in type 1 autoimmune hepatitis",
abstract = "Background and Aims: Cirrhosis connotes irreversible damage to the liver and a shortened life expectancy. The aim of this study was to evaluate the impact of cirrhosis on treatment response and survival in type 1 autoimmune hepatitis. Methods: One hundred twenty-eight patients were evaluated for histological cirrhosis. Response to treatment, predictors for cirrhosis, and outcomes were determined. Results: Thirty-seven patients (29{\%}) had histological cirrhosis at entry, whereas 36 of the 91 patients without cirrhosis (40{\%}) developed it during 39 ± 32 months. Development of cirrhosis was predicted by lower serum albumin levels (P = 0.04) and higher prothrombin times (P < 0.001) at presentation. The frequencies of remission, relapse after drug withdrawal, and treatment failure were comparable in patients with and without cirrhosis at entry. The overall 10-year survival (93{\%}) was similar to that of an age- and sex-matched cohort from the population at large (94{\%}). Ten-year survival was not different between those with and those without cirrhosis at entry (89{\%} and 90{\%}, respectively), even with transplantation as an end point. Conclusions: Patients with histological cirrhosis at presentation respond to corticosteroid therapy as well as patients without cirrhosis. Low serum albumin levels and hypoprothrombinemia at presentation predict the development of cirrhosis. Histological cirrhosis does not diminish survival expectations.",
author = "Roberts, {S. K.} and Therneau, {Terry M} and Czaja, {A. J.}",
year = "1996",
doi = "10.1053/gast.1996.v110.pm8608895",
language = "English (US)",
volume = "110",
pages = "848--857",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Prognosis of histological cirrhosis in type 1 autoimmune hepatitis

AU - Roberts, S. K.

AU - Therneau, Terry M

AU - Czaja, A. J.

PY - 1996

Y1 - 1996

N2 - Background and Aims: Cirrhosis connotes irreversible damage to the liver and a shortened life expectancy. The aim of this study was to evaluate the impact of cirrhosis on treatment response and survival in type 1 autoimmune hepatitis. Methods: One hundred twenty-eight patients were evaluated for histological cirrhosis. Response to treatment, predictors for cirrhosis, and outcomes were determined. Results: Thirty-seven patients (29%) had histological cirrhosis at entry, whereas 36 of the 91 patients without cirrhosis (40%) developed it during 39 ± 32 months. Development of cirrhosis was predicted by lower serum albumin levels (P = 0.04) and higher prothrombin times (P < 0.001) at presentation. The frequencies of remission, relapse after drug withdrawal, and treatment failure were comparable in patients with and without cirrhosis at entry. The overall 10-year survival (93%) was similar to that of an age- and sex-matched cohort from the population at large (94%). Ten-year survival was not different between those with and those without cirrhosis at entry (89% and 90%, respectively), even with transplantation as an end point. Conclusions: Patients with histological cirrhosis at presentation respond to corticosteroid therapy as well as patients without cirrhosis. Low serum albumin levels and hypoprothrombinemia at presentation predict the development of cirrhosis. Histological cirrhosis does not diminish survival expectations.

AB - Background and Aims: Cirrhosis connotes irreversible damage to the liver and a shortened life expectancy. The aim of this study was to evaluate the impact of cirrhosis on treatment response and survival in type 1 autoimmune hepatitis. Methods: One hundred twenty-eight patients were evaluated for histological cirrhosis. Response to treatment, predictors for cirrhosis, and outcomes were determined. Results: Thirty-seven patients (29%) had histological cirrhosis at entry, whereas 36 of the 91 patients without cirrhosis (40%) developed it during 39 ± 32 months. Development of cirrhosis was predicted by lower serum albumin levels (P = 0.04) and higher prothrombin times (P < 0.001) at presentation. The frequencies of remission, relapse after drug withdrawal, and treatment failure were comparable in patients with and without cirrhosis at entry. The overall 10-year survival (93%) was similar to that of an age- and sex-matched cohort from the population at large (94%). Ten-year survival was not different between those with and those without cirrhosis at entry (89% and 90%, respectively), even with transplantation as an end point. Conclusions: Patients with histological cirrhosis at presentation respond to corticosteroid therapy as well as patients without cirrhosis. Low serum albumin levels and hypoprothrombinemia at presentation predict the development of cirrhosis. Histological cirrhosis does not diminish survival expectations.

UR - http://www.scopus.com/inward/record.url?scp=0030065386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030065386&partnerID=8YFLogxK

U2 - 10.1053/gast.1996.v110.pm8608895

DO - 10.1053/gast.1996.v110.pm8608895

M3 - Article

C2 - 8608895

AN - SCOPUS:0030065386

VL - 110

SP - 848

EP - 857

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -